Osiris strikes deal with Stryker for bone-repair product

Osiris Therapeutics strikes an exclusive marketing deal with Stryker for its Bio⁴ bone-allograft product.

Osiris Therapeutics said it struck an exclusive marketing deal with Stryker (NYSE:SYK) for its Bio⁴ bone allograft.

Osiris Therapeutics Inc., Stryker Corp.

News Well, Orthopedics, Regenerative Medicine

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1xKaqr6